The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease

NCT ID: NCT01161914

Last Updated: 2016-08-23

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE3
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-01-31

Brief Summary

The purpose of this study is to compare and evaluate the efficacy and safety of ISU302, an investigational product, and Cerezyme®, comparator, for Type 1 Gaucher Disease patients

Conditions

Gaucher Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Blinding Strategy: DOUBLE

Study Groups

Cerezyme®

60 U/kg infusion (every 2 weeks for 24 weeks)

Group Type: ACTIVE_COMPARATOR

Cerezyme®

Intervention Type: DRUG

administered by IV infusion for a dose of 60 U/kg

ISU302

60 U/kg infusion (every 2 weeks for 24 weeks)

Group Type: EXPERIMENTAL

ISU302

Intervention Type: DRUG

administered by IV infusion for a dose of 60 U/kg

Interventions

Cerezyme®

administered by IV infusion for a dose of 60 U/kg

Intervention Type: DRUG

ISU302

administered by IV infusion for a dose of 60 U/kg

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• The subjects have a diagnosis of Type I Gaucher Disease
• Subjects between 2 years old and 75 years old
• Subjects documented with glucocerebrosidase deficiency
• Subjects with splenomegaly (as indicated by CT volumetric analysis as 5 times over than the standard size (0.2% of total body weight in kilograms))
• A hemoglobin concentration level:Male > 12 years of age <12.0 g/dL Female>12 years of age<11.0 g/dL Child > 2 years of age and <12 years of age <10.5 g/dL
• Platelet count of < 120,000 / ㎣
• Treatment-naive to enzyme replacement therapy (ERT) or treatment- experienced subjects who have not received ERT in the 12 months before screening and antibody test result is negative
• Treatment naive to substrate reduction therapy (SRT) or treatment- experienced subjects who have not received SRT in the 12 months before screening
• Subjects or their spouses who provide consent to use one of following contraception methods, or women in menopause. (In this case, menopause is defined as a period after 12 months from the last menstruation)
• Condoms, sponge, foams, jellies, diaphragm, or intrauterine device (Spouse or patient who had vasectomy or tubal ligation/ hysterectomy)
• Total abstinence from sexual intercourse: Female patient using oral contraceptives must use other contraception method (barrier method) also during the trial period and after the completion of trial as well as up to 90 days from the conclusion of trial.
• The subject or their legal representative has signed the informed consent.

Exclusion Criteria

• Treatment with any investigational product in 90 days before study entry
• Partial or total splenectomy
• Subjects who have a serious concurrent disease like infection or who abuse addictive drug and substances.
• Pregnant and/or breast-feeding women
• Presence of Hepatitis B surface antigen or Hepatitis C or the patients show positive reaction to human immunodeficiency virus (HIV) type1
• Subjects with a history of allergic reaction to Imiglucerase
• Subjects with a history of severe pulmonary hypertension caused by Gaucher Disease
• Any subject whom the investigator or the sub investigator considers as inad equate for this trial

• Minimum Eligible Age: 2 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

ISU Abxis Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

ISU ABXIS CO., LTD

Other Identifiers

ISU302-2008

Identifier Type: -

Identifier Source: org_study_id